A ‘blis­ter­ing’ start to M&A in 2023 stokes hopes of a mar­ket re­bound, as in­sid­ers pre­dict a surge in deals

Big drug­mak­ers have start­ed 2023 with their check­books out, sign­ing sev­er­al multi­bil­lion-dol­lar takeovers in what some in­dus­try in­sid­ers see as the start of an M&A surge fo­cused on snag­ging block­buster drugs.

The up­swing in deals fol­lows a year of falling stock prices and star­tups that have strug­gled to ac­cess pri­vate cap­i­tal. Those two trends are re­lat­ed: The draw­down has pulled down val­u­a­tions to rea­son­able lev­els at a time when phar­ma gi­ants have cash and need to re­load their pipelines. As Jef­feries an­a­lyst Michael Yee summed up in a re­cent note to in­vestors: “Low­er val­u­a­tions and hun­gry phar­ma.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER